Abbott Laboratories Aktie
WKN: 850103 / ISIN: US0028241000
29.09.2025 14:35:00
|
Abbott's Esprit BTK Dissolvable Stent Approved By Health Canada
(RTTNews) - Abbott Laboratories (ABT) on Monday announced that Health Canada has approved its dissolvable stent, the Esprit BTK Everolimus Eluting Resorbable Scaffold System.
The device is used to treat people with chronic limb threatening ischemia (CLTI) below-the-knee (BTK). It keeps arteries open and delivers the drug everolimus to support healing before the stent fully dissolves.
More than 800,000 Canadians are living with Peripheral Artery Disease (PAD). CLTI is a severe form of PAD in which arteries become clogged with plaque, blocking blood flow and oxygen to the lower leg and foot. People with CLTI often experience severe pain and non-healing open wounds.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Abbott Laboratoriesmehr Nachrichten
Analysen zu Abbott Laboratoriesmehr Analysen
Aktien in diesem Artikel
Abbott Laboratories | 113,56 | 0,37% |
|